Looking to publish in Inflammatory Bowel Diseases? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginInflammatory Bowel Diseases publishes original basic science, translational, and clinical research regarding pathogenesis, epidemiology, evaluation, and treatment of IBD that will lead to advancements in overall clinical care.
Looking to publish in Inflammatory Bowel Diseases? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginSubmission Instructions
Inflammatory Bowel Diseases accepts the following article types. Click on an article type to view submission instructions.
Review Articles
Original Articles
Brief Reports
Letters To The Editor
Clinical Practice Guidelines
Recent Publications
Screening and management of coccidioidomycosis in patients with inflammatory bowel disease on immunosuppressive therapies
Marina I Ivanov, Janis E Blair, Guilherme P Ramos
B cells regulate T cell transfer colitis by partially reconstituting luminal IgA and modulating the colonic microbiota
Josef Urrete, Margaret Kim, Amruth Chilukuri, Prabhdeep Kaur, Zining Shen, Mark Holton, Paul Jedlicka, Guillaume Urtecho, Giorgos Bamias, Jesús Rivera-Nieves
Morganella morganii -derived histamine impairs intestinal barrier function via HRH4 and aggravates colitis
Youcai Yi, Rui Feng, Xueting Wu, Xiaochen Zhu, Liyuan Xiang, Kangrong Zheng, Shu Xu, Wenhua Lai, Yijun Zhu, Minhu Chen
Response to “Isolated perianal Crohn’s disease: the next challenge is long-term surveillance”
Wasuwit Wanchaitanawong, Julajak Limsrivilai
Current evidence for first-line advanced therapies in pediatric ulcerative colitis: a critical review
Toshihiko Kakiuchi
Frequently asked questions
How long does it take to publish?
Appeals may take a minimum of 3 to 6 weeks to receive a response from the Editors. Proof corrections must be returned within 48 hours of receipt.
Reformat to Inflammatory Bowel Diseases using Livewrite PremiumIs a cover letter required?
Cover letters are mentioned for disclosure when sharing prior IBD reviews with another journal. Manuscripts posted to a preprint server must be disclosed during submission. AI use should be disclosed in cover letters to editors and in the Methods or Acknowledgements section.
Reformat to Inflammatory Bowel Diseases using Livewrite PremiumWhat are the publication costs?
Subscription journal with open access publishing options available.
Reformat to Inflammatory Bowel Diseases using Livewrite Premium